Last reviewed · How we verify
NCT06623110: INTERCEPT
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Phase 2 trial testing RP2 Injection in High-Risk Oral Precancerous Disease in 25 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Glenn J. Hanna |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 January 2025 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2029 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- RP2 Injection — full drug profile →
Conditions studied
- High-Risk Oral Precancerous Disease — all drugs for High-Risk Oral Precancerous Disease →
Sponsor
Glenn J. Hanna — full company profile →
Who can join
18 and older, any sex, with High-Risk Oral Precancerous Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
Vázquez-Arreguín K, Rivera-Caraballo KA, Ventarapragada D, Chiocca EA, et al · · 2025 · cited 6× · PMID 40702727 · DOI 10.1016/j.ymthe.2025.07.034 -
Cancer Prevention Clinical Trials: Advances and Challenges.
Francis ER, Syed FZ, Rajan A, Szabo E. · · 2026 · PMID 41681861 · DOI 10.3390/cancers18030390
Verify or expand the search:
- PubMed search for NCT06623110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Glenn J. Hanna trials
Trials by the same sponsor.
- NCT06940180 — Toripalimab With Chemotherapy for Sinus Cancer · Phase 2 · recruiting
- NCT06805617 — A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers · Phase 2 · recruiting
- NCT06239220 — PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC · Phase 2 · recruiting
- NCT05774899 — CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC · Phase 1, PHASE2 · recruiting
- NCT05057247 — Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06623110 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Glenn J. Hanna
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06623110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing